key: cord-0253854-468k5y8w
authors: Ko, C. S.; Brody, J. P.
title: A Genetic Risk Score for Glioblastoma Multiforme Based on Copy Number Variations.
date: 2021-01-26
journal: nan
DOI: 10.1101/2021.01.22.21250319
sha: 77c22df44895f3fff46ea88e9998515d4ae17c08
doc_id: 253854
cord_uid: 468k5y8w

Glioblastoma multiforme is the most common form of brain cancer. Several lines of evidence suggest that glioblastoma multiforme has a genetic basis. A genetic test that could identify people who are at high risk of developing glioblastoma multiforme could improve our understanding of this form of brain cancer. Using the Cancer Genome Atlas (TCGA) dataset, we found common germ line DNA copy number variations in the TCGA population. We tested whether different sets of these germ line DNA copy number variations could effectively distinguish patients with glioblastoma multiforme from others in the TCGA dataset. We used a gradient boosting machine, a machine learning classification algorithm, to classify TCGA patients solely based on a set of germline DNA copy number variations. We found that this machine learning algorithm could classify TCGA glioblastoma multiforme patients from the other TCGA patients with an area under the curve (AUC) of the receiver operating characteristic curve (AUC=0.875). Grouped into quintiles, the highest ranked quintile by the machine learning algorithm had an odds ratio of 3.78 (95% CI 3.25-4.40) higher than the average odds ratio and about 40 (95% CI 20-70) times higher than the lowest quintile. The identification of an effective germ line genetic test to stratify risk of developing glioblastoma multiforme should lead to a better understanding of how this cancer forms. This result might ultimately lead to better treatments of glioblastoma multiforme.

The identification of an effective germ line genetic test to stratify risk of developing glioblastoma 23 multiforme should lead to a better understanding of how this cancer forms. This result might 24 ultimately lead to better treatments of glioblastoma multiforme. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.22.21250319 doi: medRxiv preprint Introduction. 31 Glioblastoma multiforme (GBM) is the most common form of brain cancer [1] . GBM was 32 once considered a subtype of the gliomas, but evidence is accumulating that it is distinct from the 33 other gliomas [2, 3] . Glioblastoma is an aggressive form of cancer; the median survival time is 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. We used data from TCGA. TCGA was a project that collected germ line DNA from over 53 8800 patients, 499 of those patients had glioblastoma multiforme. TCGA did a thorough molecular 54 characterization of both tumor tissue and normal tissue. In this paper, we used data only derived 55 from peripheral normal blood collected from these patients.

The National Cancer Institute funded and oversaw TCGA. This project followed a 57 standardized workflow called the Genome Characterization Pipeline, consisting of four major CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.22.21250319 doi: medRxiv preprint each region [12] . These copy number values were further transformed into segment mean values 74 also known as log base 2 ratios.

The CNV data and corresponding clinical information are stored in Google BigQuery as 76 part of the Institute for Systems Biology's Cancer Genomics Cloud [13] . We wrote SQL and R 77 code to access and analyze this data.

Data analysis was performed in the statistical programming language R. We used the 79 "bigrquery" package to download the required data subsets from the cloud storage for further 80 manipulation to be trained in GBM models. The dataset was formatted such that every row 81 contained one observation, i.e., a single patient, which was denoted by case-barcode, a unique 82 identifier. Every column was defined by the genomic address of a gene segment, consisting of 83 chromosomal location, start and end base pair positions. Each cell then contained the segment 84 mean for the gene segment defined by its column for the patient recorded in that particular row.

The value could be blank ("NA") if the CNV had no information available. Lastly, the cancer 86 types that the patients had been diagnosed with were recorded in another column. 87 We trained, tested, and validated our Gradient Boosting Machine (GBM) models using is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; Table 1 . We selected copy number variations based on the number of patients in Myelogenous Leukemia (LCML), were excluded. Samples originating from patients with 107 glioblastoma multiforme were labelled GBM, while all other samples were labelled "Normal".

The models were trained with 100 trees and balanced classes, with no max depth specified, and 109 the training was followed by ten-fold cross validation to avoid overfitting and obtain the AUC 110 values for each model.

Results. 112 We have previously found that the gradient boosting algorithm performs the best on this 113 particular dataset [15] . We used the gradient boosting algorithm exclusively in this paper. 114 We first sought to characterize how the performance of the classification varied with the Each person's copy number variation is characterized by a chromosome number, start point, end 118 point, and a log base 2 ratio value. The log base 2 ratio value characterizes whether the particular 119 copy number variation is a duplication, deletion, or other variation. We found that many of these 120 copy number variations were common to many different people in the dataset. 121 We ranked the features (copy number variations) by the number of people in which the 122 feature appeared, as shown in Table 1 . This table, for instance, indicates that an 1154 bp copy 123 number variation on chromosome 3 is the most common copy number variation in the dataset, 124 appearing in 3508 of 8859 different people. We refer to this particular copy number variation as 125 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2. 166 167 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. We checked whether our copy number variation data overlaps with these three SNPs. None 183 of the three overlap with our data. The closest is the SNP rs634537, which still lies about 1.3 184 megabases away from the #15 copy number variation in our dataset shown in Table 1 accuracy of a germline test should increase by combining copy number variation data with SNP 188 data.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. it had an AUC of about 0.61 [29] . One genetic risk score to predict breast cancer risk is 217 commercially available and has been validated in several large cohorts with over 100,000 women. Our study has several limitations. We performed a reanalysis of existing data that was not 221 collected for this purpose. It would be better to design a prospective study where samples could 222 be collected ahead of time from a diverse, but well defined, group of people. Since we used a non-223 linear machine learning algorithm rather than logistic regression, we could not correct for 224 population substructure, as is typically done in GWAS studies [31] . 225 Our analysis is based on TCGA, a single dataset. Although TCGA was designed to be 226 inclusive and it included a wide selection of people with different racial and ethnic backgrounds, 227 it is not clear how well these results will generalize to any specific population. Future studies 228 should be done to validate these findings by applying these predictions to different populations 229 and testing how well they perform in a new population. 230 Finally, our control population consists of people who have been diagnosed with many 231 different types of cancer patients, but not glioblastoma multiforme. This is an unfortunate aspect 232 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.22.21250319 doi: medRxiv preprint of using the TCGA dataset. It would be better to draw the control population from the general 233 population instead of limiting it to only those who have been diagnosed with other forms of cancer.

Conclusion: 235 In conclusion, we found that glioblastoma multiform patients in TCGA dataset could be 236 distinguished from other patients solely based on germline DNA copy number variation data.

Germline DNA copy number variation data was able to distinguish people who developed 238 glioblastoma from other people with an AUC of 0.875. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.22.21250319 doi: medRxiv preprint

An integrated genomic analysis of 259 human glioblastoma multiforme

Genome-wide 262 association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma 263 and non-glioblastoma tumors

Quantifying the heritability 265 of glioma using genome-wide complex trait analysis

Glioblastoma survival in the United States before and during the temozolomide 268 era

Occurrence of Glioblastoma Multiforme in Three Generations of a Cancer 270 Family

Simultaneous presentation of glioblastoma 272 multiforme in siblings two and five years old: case report

Familial glioblastoma: A case 275 report of glioblastoma in two brothers and review of literature

Epidemiology and molecular pathology of glioma. 278

Predictive 280 testing for complex diseases using multiple genes: Fact or fiction?

Bioinformatics Pipeline: Copy Number Variation Analysis -GDC Docs

Integrated genotype calling 285 and association analysis of SNPs, common copy number polymorphisms and rare CNVs

Circular binary segmentation for the analysis of array-288 based DNA copy number data

The ISB Cancer Genomics 290 Cloud: A Flexible Cloud-Based Platform for Cancer Genomics Research

Greedy function approximation: A gradient boosting machine

Genetic risk score for ovarian cancer based on chromosomal-scale length variation. 295 medRxiv

The personal and clinical utility of polygenic risk scores

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. 301

The somatic 303 genomic landscape of glioblastoma

Mining TCGA database for genes of prognostic value in 305 glioblastoma microenvironment

Identification of prognostic gene 307 signatures of glioblastoma: a study based on TCGA data analysis

Analysis of copy number variation from germline DNA can predict individual cancer 310 risk. bioRxiv

Evaluation of a genetic risk score for severity of COVID-19 using human chromosomal-312 scale length variation

Genome-wide Analysis of Common 314

Copy Number Variation and Epithelial Ovarian Cancer Risk. Cancer epidemiology, biomarkers & 315 prevention : a publication of the American Association for Cancer Research, cosponsored by the American 316 Society of Preventive Oncology

Strongly enhanced colorectal 318 cancer risk stratification by combining family history and genetic risk score

A colorectal cancer prediction model using 321 traditional and genetic risk scores in Koreans

Cancer Risk Using Common Genetic Susceptibility Loci

Prediction of individual genetic risk 327 to prostate cancer using a polygenic score

European polygenic risk score for 329 prediction of breast cancer shows similar performance in Asian women

Development and Validation of a 332

Clinical Polygenic Risk Score to Predict Breast Cancer Risk

New approaches to population stratification in genome-335 wide association studies